Therapeutic Effect of Oral Hyaluronic Acid on Knee Osteoarthritis

Therapeutic Effect of Combined Treatment of Oral Nutritional Supplement Based on Hyaluronic Acid With Hyaluronic Acid Intra-articular Injection on Symptomatic Knee Osteoarthritis

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07033312

Enrollment

Registered

2025-06-24

Start date

2023-04-21

Completion date

2025-02-17

Last updated

2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Brief summary

The goal of this clinical trial is to investigate the effect of oral hyaluronate in patients with knee osteoarthritis. The main question it aims to answer is: the therapeutic effect in the combined treatment of oral nutritional supplement based on hyaluronic acid with hyaluronic acid intra-articular Injection on symptomatic knee osteoarthritis. Researchers will compare it to those who receive only hyaluronic acid injection to see if the combined treatment is better. Participants will receive a total of three months of oral hyaluronate or placebo agents.

Interventions

DRUGoral hyaluronate and injection

The patient receives oral hyaluronate and hyaluronate injection

DRUGhyaluronate injection

The patient receives hyaluronate injection only

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Masking description

both the patients and the investigators were blinded to the agent patients took

Eligibility

Sex/Gender

ALL

Age

60 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Radiological evidence of osteoarthritis Ahlbäck stage I-III. 2. Had knee effusion at the suprapatellar recess under ultrasonographic examination. 3. Age between 60 and 75 years old.

Exclusion criteria

1. Rheumatological disorders 2. Accidental trauma or fractures involving knees in the past three months 3. Neuropathic pain involving lower limbs 4. Central nervous system disorders including stroke, Parkinsonism, and spinal cord disorders. 5. Depression and cognitive problems 6. Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
The Western Ontario and McMaster Universities Arthritis Index (WOMAC)	From enrollment to the end of treatment at 12 weeks	The Western Ontario and McMaster Universities Arthritis Index (WOMAC) aim to reveal pain, stiffness and function of the knee, the minimum and maximum values are 0 and 68, and a higher score mean a worse outcome.

Secondary

Measure	Time frame	Description
knee strength	From enrollment to the end of treatment at 12 weeks	knee extension and flexion torque detected by isokinetic machine
Timed up and go test	From enrollment to the end of treatment at 12 weeks	the time needed for a patient sits on a chair, stands up walks for 3 meters, and then go back down

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026